Prognostic analysis of early-stage squamous cell carcinoma of the vulva
© Xu et al.; licensee BioMed Central Ltd. 2013
Received: 5 August 2012
Accepted: 23 December 2012
Published: 26 January 2013
The aim of this study was to analyze prognostic factors of early-stage squamous cell carcinoma of the vulva.
A retrospective analysis was conducted on 35 patients who were treated for early-stage squamous cell carcinoma of the vulva at Sun Yat-sen University Cancer Center from January 1980 to December 2005. The Statistical Package for Social Science (SPSS) was used to compare the different strategies of operation and to analyze the prognostic factors.
Thirty-five patients had early-stage squamous cell carcinoma of the vulva. Of these cases, 26 were well differentiated, seven were moderately differentiated, and two were poorly differentiated. The five-year survival rate was 77.1%. Five cases were in FIGO stage 1a and 30 cases were in stage 1b; median survival times were 182.3 months and 152.5 months, and the five-year survival rates were 100% and 81.5% (P >0.05), respectively. The five-year survival of the patients who underwent local excision; radical vulvectomy and en bloc resection of inguinofemoral lymphadenectomy; orradical vulvectomyen bloc resection of inguinofemoral lymphadenectomy, and pelvic lymph nodes was 50%, 81.8%, and 83.9%, respectively. For these cases, 74.3% of the tumors were medial while 25.7% were lateral, and the five-year survival rates of patients according to tumor location were 87.0% and 64.8% (P <0.05), respectively. The inguinal lymph node not increased and active were 16 cases (45.7%), and increased, active and hard were 17 cases (48.6%), and syncretic were two cases (5.7%), five-year survival rates were 73.3%, 92.9% and 50% (P <0.05), respectively. Of these cases, 74.3% of the tumors were cauliflower-like and 25.7% were nodular; five-year survival rates by tumor type were 91.3% and 66.7% (P <0.05), respectively.
For patients with early-stage squamous cell carcinoma of the vulva, surgical operation is the primary, yet the best, treatment. The related prognostic factors were tumor location (lateral/medial), stage, gross morphology, and clinical state of the inguinal lymph node.
KeywordsVulvar squamous cell carcinoma Surgical Prognosis
In primary gynecological malignancies, vulvar carcinoma is relatively rare, constituting approximately 3% to 5%. One of the most common types of vulvar carcinoma is squamous cell carcinoma, which accounts for about 90% of malignant tumors, whereas melanoma, basal cell carcinoma, Pap adenocarcinoma, sarcoma, and Paget’s disease are much less common . Early vulvar squamous cell carcinoma has not been taken seriously enough for lack of obvious symptoms.
Of the 150 patients with confirmed vulvar squamous cell carcinoma who were treated in our cancer center, 35 cases (23%) were early carcinoma (stage I). In recent years, many scholars have advocated for implementing individualized surgical treatment with different operations according to the position, depth of invasion and other risk factors in early vulvar squamous cell carcinoma cases. But identification of early incidence is relatively low, fewer cases are reported, and operation mode and prognostic factors still incite controversy. This paper sums up the clinical data of early vulvar squamous cell carcinoma for 20 years with the objective of evaluating the impact of clinicopathologic prognostic factors and different surgical methods on early-stage vulvar squamous cell carcinoma prognosis.
From January 1980 to December 2005, 35 patients with early-stage invasive squamous cell carcinoma of the vulva presented to Sun Yat-sen University Cancer Center, of which three cases were complicated with hypertension and diabetes mellitus. In these 35 cases, patient ages ranged from 30 to 79 years old (median 59.2 years). Upon presentation, patients who complained of vulva pruritus or neoplasm accounted for 91.4%, their symptoms appeared a median time of 72.2 months earlier (ranging from one month to 20 years), and the follow-up time was 3.7 to 297.7 months (median 79.7). Vulvar biopsy confirmed white spot lesions for 60% of the cases.
For these cases 74.3% of the tumors were medial type while 25.7% were lateral type. Determination of disease stage was performed according to the International Federation of Gynecology and Obstetrics (FIGO) Criteria 2009, of which five cases were in stage 1a and 30 cases were in stage 1b.
Only one case, with a large vulvar tumor (maximum diameter of 4 cm) near the urethra, received one cycle of chemotherapy preoperatively and two cycles postoperatively; the remaining cases underwent surgical treatment alone. The number of patients who underwent local excision; radical vulvectomy and en bloc resection of inguinofemoral; or radical vulvectomy, en bloc resection of inguinofemoral, and pelvic lymph nodes was two, 12 and 21 cases, respectively.
Overall survival was registered according to the time interval from diagnosis to death due to the disease. Progression-free survival was registered according to time interval from diagnosis to the inguinal region recurrence or distant metastasis. The actuarial survival and the overall survival for patient groups were calculated using the Kaplan-Meier method, while the difference in survival was assessed using the log-rank method. The impact of factors to overall survival was calculated with the Cox regression model in order to determine their independent contribution to the risk of death. Cox regression analysis was conducted in two steps. In the first step, univariate regression was estimated individually for each possible prognostic factor. In the second step, all prognostic factors from the univariate model were entered into a forward stepwise selection routine. Statistical significance in all cases was defined as P <0.05. The analysis was performed using the Statistical Packet for Social Sciences (SPSS, version 13.0). (SPSS Inc, Chicago, IL).
The five-year overall actuarial survival according to stage was 100% for clinical stage 1a and 81.5% for stage 1b. Of the 35 cases, the postoperative incision infection rate was 33.4%; severe complications such as rubber leg were not observed in the follow-up period. Five patients (14.3%) had tumor recurrence at 3.7 to 297.7 (median of 79.7) months after surgery. One patient died due to the recurrence of lung and mediastinal lymph node metastasis. One patient had a recurrence in the former location of the vulva near the urethra, and three patients had a limited recurrence in the vulva. After recurrence, a second surgical treatment was given. Surgical dissection of relapsed inguinofemoral lymph nodes or wide excision of vulvar recurrence was performed in case of local or regional recurrence. The patient with the recurrence near the urethra was treated with radiotherapy preoperatively; dosages that were delivered to the vulvar and inguinofemoral area ranged from 50–60 Gy.
Univariate analysis of overall survival and progression-free survival time
Number of patients
OS at five years (%)
PFS at five years (%)
50 to 60
Lymph node clinical state
not increased and active
increased and hard
invasion depth (mm)
1 to 4
5 to 7
Radical vulvectomy and en bloc resection of inguinofemoral lymph nodes
Radical vulvectomy and en bloc resection of inguinofemoral and pelvic lymph nodes
Multivariate analysis of overall survival and progression-free survival time
95% CI for Exp(B)
Primary cancer of the vulva is the most uncommon of all gynecological malignancies. It frequently occurs as inguinal lymph node metastasis and can invade urinary and reproductive tracts, thereby requiring, radical vulvectomy and en bloc resection of inguinofemoral lymphadenectomy. However, morbidity is impressive, seriously affecting a patient's quality of life. Early vulvar cancer confined to the vulva and with no lymph node metastasis needs much more individualized treatment. Recent research suggests that tumor stage, size, location, differentiation, depth of invasion and tumor-free margins are significant prognostic indicators [2, 3]. However, because vulvar cancer is rare, randomized studies are also rare, and identification of prognostic factors remains controversial. Andreasson et al. concluded that age and tumor differentiation are among the clinical variables with significant prognostic value . Moreover, Franckman et al. and Kosary reported a negative impact of age on survival . Podratz et al. developed a model containing clinical stage, positive groin nodes and tumor size but not age as prognostic factors . Boyce et al. included only the clinical stage . A study by the Gynecologic Oncology Group (GOG) showed that the number of positive lymph nodes is the most important independent prognostic factor . Our research involved only early vulvar squamous cell carcinoma (35 patients, all Stage 1 cases). The results showed the median survival time of the inguinal lymph node not increased and active were 162.6, and increased, active and hard were 164.0 and syncretic were 58.7 months. Five-year survival rates were 73.3%, 92.9% and 50% (P <0.05), respectively. Although clinical examination in judging the inguinal lymph node metastasis situation has certain limitations, the increased, active and hard lymph node status had better prognosis, suggesting that carcinoma cells caused a strong immune response in the lymph system, which can be more effective in killing tumor cells.
In early stage vulvar carcinoma patients, there is at trend towards individualized treatment in order to reduce morbidity and sequelae following inguinal lymph node dissection. However, recurrences in the groin are almost always fatal. A variety of modifications in groin treatment have been introduced . For patients with a stage 1a, tumor confined to the vulva with a maximum diameter of ≤2 cm and an infiltration depth ≤1 mm, there is no need to excise the inguinal lymph node . Because the risk of lymph node metastasis is negligible (<1%), a wide local excision can be used. For stage 1b of a lateral type case, the occurrence of contralateral inguinal lymph node metastasis risk is relatively low, and may therefore require only resection with ipsilateral lymph node without the contralateral lymph node. Stage 1b medial type or large unilateral lesions (diameter >2 cm) still require bilateral inguinal lymph node excision. Homesley  reported that if tumor invasive depth was ≤2 mm, ipsilateral inguinal lymph node positive rate was 61.8%, whereas for contralateral lymph nodes without metastasis but with an infiltration depth of 3 to 5 mm, contralateral lymph node positivity rate was 11.9%, and if infiltration depth was 6 to 10 mm, contralateral lymph node positivity rate was 31.8%. Therefore the author thinks that, on the premise of individual treatment, en bloc resection of inguinofemoral lymphadenectomy can reduce recurrence and metastasis rate.
For early cases, the availability of pelvic and inguinal area radiotherapy instead of en bloc resection of inguinofemoral lymphadenectomy has become a focus of debate. Perez concluded that early stage vulvar carcinoma treated by radiotherapy alone or with local excision plus adjuvant postoperative radiotherapy, can effectively reduce the incidence of complications, whereas efficacy with traditional surgery showed no difference . A prospective study by GOG randomly divided patients with negative lymph nodes into a simple inguinal radiotherapy group and an inguinal lymph node resection group. Five out of 27 patients (18.5%) who received primary groin radiation developed a groin recurrence, which is an unacceptably high failure rate, and therefore the trial was closed in advance of its original accrual goal . In 2002, Van der Velden and Ansink published a review in which they concluded that primary radiotherapy to the groin results in less morbidity but also results in a higher number of groin recurrences compared with surgery. They suggested that an operation was the preferred treatment option for early vulvar cancer patients . But a large sample, single institution experience by Katz showed the groin recurrence rate after primary radiotherapy was similar to only superficial inguinal lymphadenectomybut in a higher groin recurrence rate compared with complete inguinal lymphadenectomy . As a result, a large sample, prospective study is needed to confirm whether or not inguinal radiation is safe for early cancer treatment.
- Hacker NF: Vulvar cancer. In Practical gynecologic oncology. 3rd edition. Edited by: Berek JS, Hacker NF. Baltimore: Williams and Wilkins; 2000:553–596.
- Heaps JM, Fu YS, Montz FJ, Hacker NF, Berek JS: Surgical-pathological variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990, 38:309–314.PubMedView Article
- Piura B, Masotina A, Murdoch J, Lopes A, Morgan P, Monaghan J: Recurrent squamous cell carcinoma of the vulva: a study of 73 cases. Gynecol Oncol 1993, 48:189–195.PubMedView Article
- Andreasson B, Nyboe J: Value of prognostic parameters in squamous cell carcinoma of the vulva. Gynecol Oncol 1985, 22:341–351.PubMedView Article
- Frankman O, Kabulski Z, Nilsson B, Silfversward C: Prognostic factors in invasive squamous cell carcinoma of the vulva. Int J Gynaecol Obstet 1991, 36:219–228.PubMedView Article
- Podratz KC, Symmonds RE, Taylor WF: Carcinoma of the vulva: analysis of treatment failures. Am J Obstet Gynecol 1982, 143:340–351.PubMed
- Boyce J, Fruchter RG, Kasambilides E, Nicastri AD, Sedlis A, Remy JC: Prognostic factors in carcinoma of the vulva. Gynecol Oncol 1985, 20:364–377.PubMedView Article
- Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R: Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1991, 164:997–1003.PubMed
- Kouvaris JR, Kouloulias VE, Kondi-Pahpiti A, Kokakis JD, Vlahos LJ: Impact of inguinal dissection on prognosis of early-stage squamous cell carcinoma of the vulva-a retrospective analysis. Onkologie 2003, 26:564–567.PubMedView Article
- Gonzalez BJ, Kinney WK, Russell AH, Gaffey TA, Magrina JF, Podratz KC: Risk of occult inguinofemoral lymph node metastasis from squamous carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2003, 57:419–424.View Article
- Ayhan A, Velipasaoglu M, Salman MC, Guven S, Gultekin M, Bayraktar O: Prognostic factors for recurrence and survival in primary vulvar squamous cell cancer. Acta Obstet Gynecol Scand 2008, 87:1143–1149.PubMedView Article
- Ji Hong L: About FIGO new staging of vulvar cancer in the seventh seminar on cervical cancer in Beijing. 2010.
- Arvas M, Kose F, Gezer A, Demirkiran F, Tulunay G, Kosebay D: Radical versus conservative surgery for vulvar carcinoma. Int J Gynaecol Obstet 2005, 88:127–133.PubMedView Article
- Scheistroen M, Nesland JM, Trope C: Have patients with early squamous carcinoma of the vulva been overtreated in the past? The Norwegian experience 1977–1991. Eur J Gynaecol Oncol 2002, 23:93–103.PubMed
- Homesley HD, Bundy BN, Sedlis A, Yordan E, Berek JS, Jahshan A, Mortel R: Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). Gynecol Oncol 1993, 49:279–283.PubMedView Article
- Perez CA, Grigsby PW, Chao C, Galakatos A, Garipagaoglu M, Mutch D, Lockett MA: Irradiation in carcinoma of the vulva: factors affecting outcome. Int J Radiat Oncol Biol Phys 1998, 42:335–344.PubMedView Article
- Stehman FB, Bundy BN, Thomas G, Varia M, Okagaki T, Roberts J, Bell J, Heller PB: Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 1992, 24:389–396.PubMedView Article
- van der Velden K, Ansink A: Primary groin irradiation vs primary groin surgery for early vulvar cancer. Cochrane Database Syst Rev 2001, 4:CD002224.PubMed
- Katz A, Eifel PJ, Jhingran A, Levenback CF: The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2003, 57:409–418.PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.